ACTINOGEN MEDICAL LIMITED - Announcements

3.57%

2.9¢

Market Cap $88.91M

Healthcare Biotechnology

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel... Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.More

Corporate Spotlight

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight

Actinogen reaches 100th participant milestone

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ACW	ACW raises an addtional $3.55m under a Shortfall Placement	PRICE SENSITIVE	10/02/21	162.1KB	Share
ACW	Resignation of Dr Bill Ketelbey as Chief Executive Officer	PRICE SENSITIVE	08/02/21	158.41KB	Share
ACW	FDA Grants ACW Rare Paediatric Disease Designation in FXS	PRICE SENSITIVE	05/02/21	208.32KB	Share
ACW	Pause in Trading	PRICE SENSITIVE	05/02/21	115.67KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/01/21	244.82KB	Share
ACW	Completion of Entitlement Offer	PRICE SENSITIVE	13/11/20	198.25KB	Share
ACW	Actinogen files new patent applications	PRICE SENSITIVE	09/11/20	199.08KB	Share
ACW	FDA IND Update	PRICE SENSITIVE	04/11/20	161.63KB	Share
ACW	ACW to initiate XanaFX clinical trial in Fragile X syndrome	PRICE SENSITIVE	02/11/20	1.16MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/10/20	328.98KB	Share
ACW	R&D Tax Incentive Rebate received of A$2.9 million	PRICE SENSITIVE	27/10/20	191.49KB	Share
ACW	Offer Booklet	PRICE SENSITIVE	23/10/20	765.31KB	Share
ACW	Actinogen Presentation & Planned Conference Call	PRICE SENSITIVE	15/10/20	2.73MB	Share
ACW	Proposed issue of Securities - ACW	PRICE SENSITIVE	15/10/20	36.63KB	Share
ACW	ACW announces two clinical trials & launches capital raising	PRICE SENSITIVE	15/10/20	219.11KB	Share
ACW	Trading Halt	PRICE SENSITIVE	13/10/20	131.2KB	Share
ACW	Appendix 4E & Annual Report	PRICE SENSITIVE	26/08/20	1.05MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/07/20	331.08KB	Share
ACW	Response to ASX Price Query	PRICE SENSITIVE	01/07/20	254.37KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	23/04/20	228.75KB	Share
ACW	Market Update COVID-19	PRICE SENSITIVE	26/03/20	159.31KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	20/02/20	789.69KB	Share
ACW	December 2019 Quarterly Update	PRICE SENSITIVE	28/01/20	368.91KB	Share
ACW	Response to ASX Price Query	PRICE SENSITIVE	20/11/19	272.08KB	Share
ACW	R&D Tax Incentive rebate received of $4.58 million	PRICE SENSITIVE	24/10/19	140.48KB	Share
ACW	September 2019 Quarterly Update	PRICE SENSITIVE	24/10/19	302.11KB	Share
ACW	Cognitive improvement demonstrated with Xanamem	PRICE SENSITIVE	01/10/19	2.63MB	Share
ACW	Trading Halt	PRICE SENSITIVE	27/09/19	232.45KB	Share
ACW	Appendix 4E & Annual Report	PRICE SENSITIVE	16/08/19	1.79MB	Share
ACW	June 2019 Quarterly Update	PRICE SENSITIVE	30/07/19	237.23KB	Share
ACW	Xanamen Clinical Development & Investor Update	PRICE SENSITIVE	26/06/19	2.47MB	Share
ACW	XanaHES Trial to Continue	PRICE SENSITIVE	29/05/19	142.12KB	Share
ACW	Phase II Alzheimer's Disease Trial - results	PRICE SENSITIVE	07/05/19	145.16KB	Share
ACW	Trading Halt	PRICE SENSITIVE	03/05/19	234.39KB	Share
ACW	March 2019 Quarterly Update	PRICE SENSITIVE	24/04/19	295.74KB	Share
ACW	New Clinical Development Opportunities for Xanamem	PRICE SENSITIVE	10/04/19	141.79KB	Share
ACW	DSMB again reaffirms XanADu trial to continue without change	PRICE SENSITIVE	26/03/19	135.23KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	22/02/19	671.9KB	Share
ACW	1st participant dosed in important new Xanamem study-XanaHES	PRICE SENSITIVE	11/02/19	137.29KB	Share
ACW	December 2018 Quarterly Update	PRICE SENSITIVE	29/01/19	237.64KB	Share
ACW	Final patient enrolled in landmark Alzheimer's trial-XanADu	PRICE SENSITIVE	26/11/18	132.3KB	Share
ACW	September 2018 Quarterly Update	PRICE SENSITIVE	31/10/18	238.76KB	Share
ACW	Recruitment to close for important Alzheimer's trial-XanADu	PRICE SENSITIVE	22/10/18	134.26KB	Share
ACW	R&D Tax Rebate Received Totalling $3.15 Million	PRICE SENSITIVE	10/10/18	138.04KB	Share
ACW	Appendix 4E & Financial Statements	PRICE SENSITIVE	29/08/18	1.56MB	Share
ACW	DSMB reaffirms that XanADu continue without change	PRICE SENSITIVE	22/08/18	133.21KB	Share
ACW	XanADu Patient Enrolment Advancing Towards Completion	PRICE SENSITIVE	15/08/18	159.37KB	Share
ACW	Updated Xanamem Clinical Development Program	PRICE SENSITIVE	30/07/18	135.28KB	Share
ACW	June 2018 Quarterly Report	PRICE SENSITIVE	25/07/18	266.02KB	Share
ACW	Placement under Share Purchase Plan Shortfall	PRICE SENSITIVE	17/07/18	137.83KB	Share
ACW	New Study Sites Added to Accelarate Patient Recruitment	PRICE SENSITIVE	06/07/18	130.82KB	Share
ACW	Share Purchase Plan	PRICE SENSITIVE	06/06/18	258.09KB	Share
ACW	$15m Placement Completed-Including US Cornerstone Investor	PRICE SENSITIVE	23/05/18	206.42KB	Share
ACW	XanADu Interim Analysis-Continuation Without Change	PRICE SENSITIVE	23/05/18	191.01KB	Share
ACW	Trading Halt	PRICE SENSITIVE	21/05/18	207.68KB	Share
ACW	March 2018 Quarterly Report	PRICE SENSITIVE	26/04/18	301.69KB	Share
ACW	Mid-Way Point Reached in Landmark Alzheimer's Trial - XanADu	PRICE SENSITIVE	21/03/18	158.89KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	15/02/18	901.9KB	Share
ACW	Strong Recruitment Progress in Alzheimer's Trial	PRICE SENSITIVE	12/02/18	135.46KB	Share
ACW	New Data Supports Cortisol Hypothesis	PRICE SENSITIVE	06/02/18	208.21KB	Share
ACW	December 2017 Quarterly Report	PRICE SENSITIVE	31/01/18	255.99KB	Share
ACW	Prospectus	PRICE SENSITIVE	01/12/17	322.98KB	Share
ACW	Early Efficacy & Safety Data Planned for XanADu Trial	PRICE SENSITIVE	29/11/17	137.06KB	Share
ACW	Placement Fully Funds Completion of XanADu Alzheimer's Trial	PRICE SENSITIVE	29/11/17	144.04KB	Share
ACW	Trading Halt	PRICE SENSITIVE	27/11/17	221.04KB	Share
ACW	R&D Rebate Received Totalling $1.22 Million	PRICE SENSITIVE	15/11/17	126.71KB	Share
ACW	Quarterly Update & Appendix 4C	PRICE SENSITIVE	30/10/17	267.24KB	Share
ACW	Final Major Market Patent Granted for Xanamem	PRICE SENSITIVE	11/10/17	132.68KB	Share
ACW	First Patient Completes Landmark Alzheimer's Disease Trial	PRICE SENSITIVE	07/09/17	159.41KB	Share
ACW	Appendix 4E & Financial Statements	PRICE SENSITIVE	18/08/17	1.39MB	Share
ACW	First UK patient treated in ground-breaking clinical trial	PRICE SENSITIVE	16/08/17	167.64KB	Share
ACW	June Quarterly Update	PRICE SENSITIVE	26/07/17	256.59KB	Share
ACW	First US Patients Treated in Landmark Alzheimer's Trial	PRICE SENSITIVE	22/06/17	141.76KB	Share
ACW	First UK Site Goes Live in Global Alzheimer's Clinical Trial	PRICE SENSITIVE	01/06/17	136.04KB	Share
ACW	First Patient Treated in Landmark Alzheimer's Clinical Trial	PRICE SENSITIVE	16/05/17	143.19KB	Share
ACW	March Quarterly Update	PRICE SENSITIVE	26/04/17	262.94KB	Share
ACW	TGA Regulatory Approval for Alzheimer's Phase II Trial	PRICE SENSITIVE	08/03/17	114.8KB	Share
ACW	Actinogen Medical Financial Results	PRICE SENSITIVE	27/02/17	718.2KB	Share
ACW	UK Regulatory Approval for Alzheimer's Clinical Trial-XanADu	PRICE SENSITIVE	10/02/17	134.23KB	Share
ACW	Xanamem Research Published in Prestigious Medical Journal	PRICE SENSITIVE	09/02/17	158.45KB	Share
ACW	Appendix 4C - quarterly	PRICE SENSITIVE	23/01/17	48.42KB	Share
ACW	FDA Approval to Commence Alzheimer's Disease Clinical Trial	PRICE SENSITIVE	03/01/17	116.67KB	Share
ACW	Trading Halt	PRICE SENSITIVE	30/12/16	202.78KB	Share
ACW	Significant Advance in Development of Alzheimer's Drug	PRICE SENSITIVE	19/12/16	157.04KB	Share
ACW	Appendix 4C - quarterly-ACW.AX	PRICE SENSITIVE	26/10/16	48.32KB	Share
ACW	FDA Feedback on Xanamem Alzheimer's Trail-ACW.AX	PRICE SENSITIVE	29/09/16	105.12KB	Share
ACW	R&D Tax Rebate-ACW.AX	PRICE SENSITIVE	05/09/16	104.59KB	Share
ACW	Appendix 4E & Financial Statements-ACW.AX	PRICE SENSITIVE	31/08/16	2.55MB	Share
ACW	Landmark Research on Excess Cortisol & Alzheimer's Disease-ACW.AX	PRICE SENSITIVE	28/07/16	202.76KB	Share
ACW	US Patent Granted-Further Extends Xanamem Protection-ACW.AX	PRICE SENSITIVE	20/07/16	120.15KB	Share
ACW	Appendix 4C - quarterly-ACW.AX	PRICE SENSITIVE	15/07/16	83.2KB	Share
ACW	US FDA Feedback Enhances Alzheimers Study-ACW.AX	PRICE SENSITIVE	08/06/16	111.02KB	Share
ACW	Appendix 4C - quarterly-ACW.AX	PRICE SENSITIVE	15/04/16	83.08KB	Share
ACW	Launch of XanADu Phase II Clinical Trial	PRICE SENSITIVE	22/03/16	140.86KB	Share
ACW	Appendix 4D & Half Year Report	PRICE SENSITIVE	19/02/16	611.69KB	Share
ACW	R&D Rebate	PRICE SENSITIVE	09/02/16	95.27KB	Share
ACW	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/16	83KB	Share
ACW	Appendix 4C - quarterly	PRICE SENSITIVE	15/10/15	82.27KB	Share
ACW	Positive Trial Results for Alzheimers Drug Xanamem	PRICE SENSITIVE	29/09/15	153.84KB	Share
ACW	Trading Halt	PRICE SENSITIVE	28/09/15	367.84KB	Share

ACW ACW raises an addtional $3.55m under a Shortfall Placement
10/02/21	PRICE SENSITIVE	162.1KB	Share
ACW Resignation of Dr Bill Ketelbey as Chief Executive Officer
08/02/21	PRICE SENSITIVE	158.41KB	Share
ACW FDA Grants ACW Rare Paediatric Disease Designation in FXS
05/02/21	PRICE SENSITIVE	208.32KB	Share
ACW Pause in Trading
05/02/21	PRICE SENSITIVE	115.67KB	Share
ACW Quarterly Activity Report & Appendix 4C
29/01/21	PRICE SENSITIVE	244.82KB	Share
ACW Completion of Entitlement Offer
13/11/20	PRICE SENSITIVE	198.25KB	Share
ACW Actinogen files new patent applications
09/11/20	PRICE SENSITIVE	199.08KB	Share
ACW FDA IND Update
04/11/20	PRICE SENSITIVE	161.63KB	Share
ACW ACW to initiate XanaFX clinical trial in Fragile X syndrome
02/11/20	PRICE SENSITIVE	1.16MB	Share
ACW Quarterly Activity Report & Appendix 4C
29/10/20	PRICE SENSITIVE	328.98KB	Share
ACW R&D Tax Incentive Rebate received of A$2.9 million
27/10/20	PRICE SENSITIVE	191.49KB	Share
ACW Offer Booklet
23/10/20	PRICE SENSITIVE	765.31KB	Share
ACW Actinogen Presentation & Planned Conference Call
15/10/20	PRICE SENSITIVE	2.73MB	Share
ACW Proposed issue of Securities - ACW
15/10/20	PRICE SENSITIVE	36.63KB	Share
ACW ACW announces two clinical trials & launches capital raising
15/10/20	PRICE SENSITIVE	219.11KB	Share
ACW Trading Halt
13/10/20	PRICE SENSITIVE	131.2KB	Share
ACW Appendix 4E & Annual Report
26/08/20	PRICE SENSITIVE	1.05MB	Share
ACW Quarterly Activity Report & Appendix 4C
29/07/20	PRICE SENSITIVE	331.08KB	Share
ACW Response to ASX Price Query
01/07/20	PRICE SENSITIVE	254.37KB	Share
ACW Quarterly Activity Report & Appendix 4C
23/04/20	PRICE SENSITIVE	228.75KB	Share
ACW Market Update COVID-19
26/03/20	PRICE SENSITIVE	159.31KB	Share
ACW Appendix 4D & Half-Year Financial Statements
20/02/20	PRICE SENSITIVE	789.69KB	Share
ACW December 2019 Quarterly Update
28/01/20	PRICE SENSITIVE	368.91KB	Share
ACW Response to ASX Price Query
20/11/19	PRICE SENSITIVE	272.08KB	Share
ACW R&D Tax Incentive rebate received of $4.58 million
24/10/19	PRICE SENSITIVE	140.48KB	Share
ACW September 2019 Quarterly Update
24/10/19	PRICE SENSITIVE	302.11KB	Share
ACW Cognitive improvement demonstrated with Xanamem
01/10/19	PRICE SENSITIVE	2.63MB	Share
ACW Trading Halt
27/09/19	PRICE SENSITIVE	232.45KB	Share
ACW Appendix 4E & Annual Report
16/08/19	PRICE SENSITIVE	1.79MB	Share
ACW June 2019 Quarterly Update
30/07/19	PRICE SENSITIVE	237.23KB	Share
ACW Xanamen Clinical Development & Investor Update
26/06/19	PRICE SENSITIVE	2.47MB	Share
ACW XanaHES Trial to Continue
29/05/19	PRICE SENSITIVE	142.12KB	Share
ACW Phase II Alzheimer's Disease Trial - results
07/05/19	PRICE SENSITIVE	145.16KB	Share
ACW Trading Halt
03/05/19	PRICE SENSITIVE	234.39KB	Share
ACW March 2019 Quarterly Update
24/04/19	PRICE SENSITIVE	295.74KB	Share
ACW New Clinical Development Opportunities for Xanamem
10/04/19	PRICE SENSITIVE	141.79KB	Share
ACW DSMB again reaffirms XanADu trial to continue without change
26/03/19	PRICE SENSITIVE	135.23KB	Share
ACW Appendix 4D & Half-Year Financial Statements
22/02/19	PRICE SENSITIVE	671.9KB	Share
ACW 1st participant dosed in important new Xanamem study-XanaHES
11/02/19	PRICE SENSITIVE	137.29KB	Share
ACW December 2018 Quarterly Update
29/01/19	PRICE SENSITIVE	237.64KB	Share
ACW Final patient enrolled in landmark Alzheimer's trial-XanADu
26/11/18	PRICE SENSITIVE	132.3KB	Share
ACW September 2018 Quarterly Update
31/10/18	PRICE SENSITIVE	238.76KB	Share
ACW Recruitment to close for important Alzheimer's trial-XanADu
22/10/18	PRICE SENSITIVE	134.26KB	Share
ACW R&D Tax Rebate Received Totalling $3.15 Million
10/10/18	PRICE SENSITIVE	138.04KB	Share
ACW Appendix 4E & Financial Statements
29/08/18	PRICE SENSITIVE	1.56MB	Share
ACW DSMB reaffirms that XanADu continue without change
22/08/18	PRICE SENSITIVE	133.21KB	Share
ACW XanADu Patient Enrolment Advancing Towards Completion
15/08/18	PRICE SENSITIVE	159.37KB	Share
ACW Updated Xanamem Clinical Development Program
30/07/18	PRICE SENSITIVE	135.28KB	Share
ACW June 2018 Quarterly Report
25/07/18	PRICE SENSITIVE	266.02KB	Share
ACW Placement under Share Purchase Plan Shortfall
17/07/18	PRICE SENSITIVE	137.83KB	Share
ACW New Study Sites Added to Accelarate Patient Recruitment
06/07/18	PRICE SENSITIVE	130.82KB	Share
ACW Share Purchase Plan
06/06/18	PRICE SENSITIVE	258.09KB	Share
ACW $15m Placement Completed-Including US Cornerstone Investor
23/05/18	PRICE SENSITIVE	206.42KB	Share
ACW XanADu Interim Analysis-Continuation Without Change
23/05/18	PRICE SENSITIVE	191.01KB	Share
ACW Trading Halt
21/05/18	PRICE SENSITIVE	207.68KB	Share
ACW March 2018 Quarterly Report
26/04/18	PRICE SENSITIVE	301.69KB	Share
ACW Mid-Way Point Reached in Landmark Alzheimer's Trial - XanADu
21/03/18	PRICE SENSITIVE	158.89KB	Share
ACW Appendix 4D & Half-Year Financial Statements
15/02/18	PRICE SENSITIVE	901.9KB	Share
ACW Strong Recruitment Progress in Alzheimer's Trial
12/02/18	PRICE SENSITIVE	135.46KB	Share
ACW New Data Supports Cortisol Hypothesis
06/02/18	PRICE SENSITIVE	208.21KB	Share
ACW December 2017 Quarterly Report
31/01/18	PRICE SENSITIVE	255.99KB	Share
ACW Prospectus
01/12/17	PRICE SENSITIVE	322.98KB	Share
ACW Early Efficacy & Safety Data Planned for XanADu Trial
29/11/17	PRICE SENSITIVE	137.06KB	Share
ACW Placement Fully Funds Completion of XanADu Alzheimer's Trial
29/11/17	PRICE SENSITIVE	144.04KB	Share
ACW Trading Halt
27/11/17	PRICE SENSITIVE	221.04KB	Share
ACW R&D Rebate Received Totalling $1.22 Million
15/11/17	PRICE SENSITIVE	126.71KB	Share
ACW Quarterly Update & Appendix 4C
30/10/17	PRICE SENSITIVE	267.24KB	Share
ACW Final Major Market Patent Granted for Xanamem
11/10/17	PRICE SENSITIVE	132.68KB	Share
ACW First Patient Completes Landmark Alzheimer's Disease Trial
07/09/17	PRICE SENSITIVE	159.41KB	Share
ACW Appendix 4E & Financial Statements
18/08/17	PRICE SENSITIVE	1.39MB	Share
ACW First UK patient treated in ground-breaking clinical trial
16/08/17	PRICE SENSITIVE	167.64KB	Share
ACW June Quarterly Update
26/07/17	PRICE SENSITIVE	256.59KB	Share
ACW First US Patients Treated in Landmark Alzheimer's Trial
22/06/17	PRICE SENSITIVE	141.76KB	Share
ACW First UK Site Goes Live in Global Alzheimer's Clinical Trial
01/06/17	PRICE SENSITIVE	136.04KB	Share
ACW First Patient Treated in Landmark Alzheimer's Clinical Trial
16/05/17	PRICE SENSITIVE	143.19KB	Share
ACW March Quarterly Update
26/04/17	PRICE SENSITIVE	262.94KB	Share
ACW TGA Regulatory Approval for Alzheimer's Phase II Trial
08/03/17	PRICE SENSITIVE	114.8KB	Share
ACW Actinogen Medical Financial Results
27/02/17	PRICE SENSITIVE	718.2KB	Share
ACW UK Regulatory Approval for Alzheimer's Clinical Trial-XanADu
10/02/17	PRICE SENSITIVE	134.23KB	Share
ACW Xanamem Research Published in Prestigious Medical Journal
09/02/17	PRICE SENSITIVE	158.45KB	Share
ACW Appendix 4C - quarterly
23/01/17	PRICE SENSITIVE	48.42KB	Share
ACW FDA Approval to Commence Alzheimer's Disease Clinical Trial
03/01/17	PRICE SENSITIVE	116.67KB	Share
ACW Trading Halt
30/12/16	PRICE SENSITIVE	202.78KB	Share
ACW Significant Advance in Development of Alzheimer's Drug
19/12/16	PRICE SENSITIVE	157.04KB	Share
ACW Appendix 4C - quarterly-ACW.AX
26/10/16	PRICE SENSITIVE	48.32KB	Share
ACW FDA Feedback on Xanamem Alzheimer's Trail-ACW.AX
29/09/16	PRICE SENSITIVE	105.12KB	Share
ACW R&D Tax Rebate-ACW.AX
05/09/16	PRICE SENSITIVE	104.59KB	Share
ACW Appendix 4E & Financial Statements-ACW.AX
31/08/16	PRICE SENSITIVE	2.55MB	Share
ACW Landmark Research on Excess Cortisol & Alzheimer's Disease-ACW.AX
28/07/16	PRICE SENSITIVE	202.76KB	Share
ACW US Patent Granted-Further Extends Xanamem Protection-ACW.AX
20/07/16	PRICE SENSITIVE	120.15KB	Share
ACW Appendix 4C - quarterly-ACW.AX
15/07/16	PRICE SENSITIVE	83.2KB	Share
ACW US FDA Feedback Enhances Alzheimers Study-ACW.AX
08/06/16	PRICE SENSITIVE	111.02KB	Share
ACW Appendix 4C - quarterly-ACW.AX
15/04/16	PRICE SENSITIVE	83.08KB	Share
ACW Launch of XanADu Phase II Clinical Trial
22/03/16	PRICE SENSITIVE	140.86KB	Share
ACW Appendix 4D & Half Year Report
19/02/16	PRICE SENSITIVE	611.69KB	Share
ACW R&D Rebate
09/02/16	PRICE SENSITIVE	95.27KB	Share
ACW Appendix 4C - quarterly
27/01/16	PRICE SENSITIVE	83KB	Share
ACW Appendix 4C - quarterly
15/10/15	PRICE SENSITIVE	82.27KB	Share
ACW Positive Trial Results for Alzheimers Drug Xanamem
29/09/15	PRICE SENSITIVE	153.84KB	Share
ACW Trading Halt
28/09/15	PRICE SENSITIVE	367.84KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 2.9¢		Change 0.001(3.57%)		Mkt cap ! $88.91M

Open	High	Low	Value	Volume
2.9¢	2.9¢	2.9¢	$8	276

Buyers (Bids)

No.	Vol.	Price($)
4	2131428	2.8¢

Sellers (Offers)

Price($)	Vol.	No.
2.9¢	1331801	6

View Market Depth

No.	Vol.	Price($)
4	2131428	0.028
4	2388449	0.027
6	2648855	0.026
14	2431589	0.025
7	1984166	0.024

Price($)	Vol.	No.
0.029	1331801	6
0.030	3458964	8
0.031	539999	3
0.032	2514250	6
0.033	981127	8

Last trade - 09.59am 12/09/2025 (20 minute delay)

ACW (ASX) Chart

ACTINOGEN MEDICAL LIMITED - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories